Search Results - "Pangan, A"

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases by Burmester, G R, Mease, P, Dijkmans, B A C, Gordon, K, Lovell, D, Panaccione, R, Perez, J, Pangan, A L

“…Clinical trials of tumour necrosis factor antagonists have raised questions about the potential risk of certain serious adverse events (SAE). To assess the…”
Get more information

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis by Schiff, M H, Burmester, G R, Kent, J D, Pangan, A L, Kupper, H, Fitzpatrick, S B, Donovan, C

“…Objective: To assess the safety of adalimumab in global clinical trials and postmarketing surveillance among patients with rheumatoid arthritis (RA). Methods:…”
Get full text

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis by van der Heijde, D, Pangan, A L, Schiff, M H, Braun, J, Borofsky, M, Torre, J, Davis, Jr, J C, Wong, R L, Kupper, H, Collantes, E

“…To evaluate the long-term safety and efficacy of adalimumab in patients with ankylosing spondylitis (AS) and total spinal ankylosis (TSA). Patients (n = 315)…”
Get more information

Selective area metalorganic vapor-phase epitaxy of gallium arsenide on silicon by Cheng, S.F., Gao, L., Woo, R.L., Pangan, A., Malouf, G., Goorsky, M.S., Wang, K.L., Hicks, R.F.

“…The selective area, metalorganic vapor-phase epitaxy of gallium arsenide on silicon substrates was investigated. Low-temperature arsenic passivation of the…”
Get full text

Hemarthrosis as initial presentation of scurvy by LORENZO PANGAN, Aileen, ROBINSON, Dwight

“…Vitamin C deficiency or scurvy is a disease now rarely seen except for certain populations at risk. When it occurs, diagnosis can be difficult as it can mimic…”
Get full text

P556 The effect of multiple doses of upadacitinib 45 mg on the pharmacokinetics of cytochrome P450 substrates in healthy adult subjects by Ibrahim, M, Pangan, A, Feng, T, Mohamed, M E

Get full text

060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate by Smolen, J S, Cohen, S, Emery, P, Rigby, W, Tanaka, Y, Zhang, Y, Friedman, A, Othman, A A, Camp, H S, Pangan, A L

Get full text

059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis by van Vollenhoven, R, Takeuchi, T, Pangan, A L, Friedman, A, Mohamed, M F, Chen, S, Rischmueller, M, Blanco, R, Xavier, R M, Strand, V

Get full text

P378 Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study by Feagan, B, Sandborn, W, Schreiber, S, Huang, B, Alperovich, G, Pangan, A, Lacerda, A, D’Haens, G

“…Abstract Background The SES-CD is a validated and widely used outcome measure in clinical trials. We assessed the efficacy of upadacitinib (UPA), an oral…”
Get full text

OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study by Danese, S, Vermeire, S, Zhou, W, Pangan, A, Siffledeen, J, Hébuterne, X, Nakase, H, Higgins, P, Chen, M H, Sanchez-Gonzalez, Y, Huang, B, Xie, W, Liu, J, Weinreich, M, Pannaccione, R

Get full text

Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients by Köller, Marcus D., Aletaha, Daniel, Funovits, Julia, Pangan, Aileen, Baker, Daniel, Smolen, Josef S.

“…Objective. To compare the efficacy of MTX and MTX+TNF inhibitors (TNFis) in elderly patients with RA with that in patients of younger age. Methods. Data from…”
Get full text

OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study by Vermeire, S, Danese, S, Zhou, W, Pangan, A, Greenbloom, S, D’Haens, G, Panes, J, Juillerat, P, Lindsay, J O, Loftus Jr, E V, Sandborn, W J, Reinisch, W, Sanchez Gonzalez, Y, Huang, B, Xie, W, Liu, J, Weinreich, M A, Panaccione, R

Get full text

Vitamin D pathway modulation in Caucasian case series of healthy women and breast cancer patients by Mercatali, L., Masalu, N., Bongiovanni, A., Pangan, A., Tedaldi, R., Scarpi, E., La Manna, F., Liverani, C., Spadazzi, C., Ibrahim, T., Amadori, D., Serra, P.

Get full text

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY by Panaccione, R, Danese, S, Zhouwen, W, Pangan, A, Hébuterne, X, Nakase, H, D’Haens, G, Panes, J, Lindsay, J, Higgins, P, Loftus, E, Sandborn, W, Xie, W, Sanchez gonzalez, Y, Liu, J, Weinreich, M, Vermeire, S

Get full text

P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study by Panes, J, Sandborn, W J, Loftus Jr, E V, Van Assche, G, Ghosh, S, Zhou, Q, Goteti, S, Enejosa, J V, Pangan, A L, Lacerda, A P

“…Abstract Background The efficacy and safety of upadacitinib (UPA), an oral selective JAK1 inhibitor, as induction therapy were reported in patients with…”
Get full text

P601 Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study by Panaccione, R, Atreya, R, Ferrante, M, Dubinsky, M C, Sands, B E, Abreu, M T, Cataldi, F, Enejosa, J V, Zhou, Q, Huang, B, Lacerda, A P, Pangan, A L

“…Abstract Background The efficacy and safety of upadacitinib (UPA), an oral selective JAK1 inhibitor, were assessed in patients with moderate-to-severe Crohn’s…”
Get full text

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) by Sieper, Joachim, van der Heijde, Désirée, Dougados, Maxime, Mease, Philip J, Maksymowych, Walter P, Brown, Matthew A, Arora, Vipin, Pangan, Aileen L

“…To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Patients fulfilled Assessment of…”
Get more information

PMS43 IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS? by Gooch, K, Feeny, DH, Wong, R, Pangan, A, Revicki, D, van der Heijde, D

Get full text

Adalimumab Safety in Crohnʼs Disease and Rheumatoid Arthritis Clinical Trials, Reduced Mortality in Rheumatoid Arthritis: 1160 by Burmester, G. R., Panaccione, R., Kent, J. D., Pangan, A. L.

Get full text

Safety analyses of adalimumab (HUMIRA) in global clinical triafs and US postmarketing surveillance of patients with rheumatoid arthritis by SCHIFF, M. H, BURMESTER, G. R, KENT, J. D, PANGAN, A. L, KUPPER, H, FITZPATRICK, S. B, DONOVAN, C

Get full text